Dysmetabolism linked to HIV-1 protease-inhibitors treatment: Review and own casistic;Sindrome dismetabolica da inibitori della HIV-1 proteasi. Revisione della letteratura e dati personali

Recenti Progressi in Medicina

Volumn 91, Issue 2, 2000, Pages 76-85

  Urso, Rocco ^a,c   Croce, Gian Franco ^a   Tubili, Claudio ^b   De Marco, Michele ^a   La Scala, Patrizia ^a   Luglio, Domenico ^a   Narciso, Pasquale ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Diabetes; HIV; Hypertriglyceridaemia; Insulin resistance; Lipid lowering agents; Lipodystrophy; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; C PEPTIDE; CYTOCHROME P450 3A; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEINASE INHIBITOR; RETINOIC ACID BINDING PROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR RISK; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULINEMIA; LIPID STORAGE; LIPODYSTROPHY; REVIEW;

ANTILIPEMIC AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERTRIGLYCERIDEMIA; IATROGENIC DISEASE; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; RISK FACTORS;

EID: 0034057085     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Palella FJ Jr, Kathleen MD, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. NEJM 1998, 338 (13): 853-66.
2. Silva M, Skolnik PR, Sherwood LG et al. The effect of protease inhibitors on weight on body composition in HIV infected patients. AIDS 1998; 12: 1645-51.
3. Lipsky JJ. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 1998, 351: 847-8.
4. Flexner C. HIV-Protease Inhibitors. NEJM 1998; 338: 1281-92
5. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. NEJM 1987; 316: 379-85.
6. th Intern Conf on AIDS, Yokohama 7-12 August 1994; 10, 2, 97 abs. PAO 269.
7. Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. NEJM 1992; 327: 329-37.
8. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the Acquired Immune Deficiency Syndrome. Endocrine reviews by the Endocrine Society, 1996; 17: 518-32.
9. Rovira E, Belda A, Martinez MD, Gonzalvo F, Pascual JM, Redon J. The prognostic value of plasma triglycerides in human immunodeficiency virus infection. Rev Clin Esp 1995; 195: 455-8.
10. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938-9.
11. th World AIDS Conference, Geneva, 28/6/-3/7/1998; abstract 12375.
12. th World AIDS Conference, Geneva, 28/6/-3/7/1998; abstract 12381.
13. Carr A, Samaras K, Burton S et al. Asyndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
14. Di Perri G, Del Bravo P, Concia E. HIV-Protease inhibitors. NEJM 1998; 339: 773-4.
15. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and Gemfibrozil for protease-inhibitor related lipid abnormalities. Lancet 1998; 352: 1031.
16. th Conference on Retroviruses and opportunistic infections. January 31-February 4, 1999, Chicago. Abstract 671.
17. Henry K, Melroe H, Huebesch J. Severe premature coronary artery disease with protease inhibitors, Lancet 1998; 351: 1328.
18. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with use of HIV protease inhibitors (correspondence). Lancet 1998; 351: 1958.
19. Gallet B, Pulik M, Genet P, Chedin P, Hiltgen M. Vascular complications associated with use of HIV protease inhibitors (correspondence). Lancet 1998; 351: 1958-59.
20. Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors (correspondence). Lancet 1998; 351: 1959.
21. Laurence J. Vascular complications associated with use of HIV protease inhibitors (correspondence). Lancet 1998; 351: 1960.
22. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Pubblic Health Advisory, June 1997.
23. Dube MP, Johnson DL, Courrier JS, Leedom JM. Protease inhibitor-associated hyperglycemia. Lancet 1997; 350: 713-4.
24. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1- infected patients. AIDS 1998; 12: F167-F173.
25. th ICAAC, Toronto, 1997. Abstract LB-8.
26. th Conference on Retroviruses and Opportunistic Infections. January 31-February 4, 1999, Chicago. Abstract 653.
27. th Conference on Retroviruses and Opportunistic Infections. January 31-February 4, 1999, Chicago. Abstract 654.
28. Hengel RL, Watts NB, Lennox JL: Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997, 350:1596
29. Viraben R, Aquilina C. Indinavir associated lipodystrophy. AIDS 1998; 12: F37-F39.
30. th World AIDS Conference, Geneva, 28/6 - 3/7/98. Abstract 12299.
31. Martinez E, Gatell JM. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr Opin Infect Dis 1999; 12: 13-9.
32. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV infection. Lancet 1998; 351: 867-70.
33. De Luca A, Murri R, Damiano F, Ammassari A, Antinori A. "Buffalo hump" in HIV-1 infection (correspondence). Lancet 1998; 352: 320.
34. Saint-Marc T, Touraine JL. "Buffalo hump" in HIV-1 infection (correspondence). Lancet 1998; 352: 319-20.
35. th Conference on Retroviruses and Opportunistic Infections. January 31-February 4, 1999, Chicago. Abstract 674.
36. th Conference on Retroviruses and Opportunistic Infections. January 31-February 4, 1999, Chicago. Abstract 642.
37. Carr A, Samaras K, Thorisdottir A, Kauffmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-99.
38. Coward WA, Parkinson SA, Murgotroyd PR. Body composition measurements for nutrition research. Nutr Res Rev 1989; 1: 115-24.
39. Tubili C. Bioimpedenzometria e diagnostica nutrizionale. In: Del Toma E (a cura di). Dietoterapia e Nutrizione clinica. Roma: Il Pensiero Scientifico Editore 1995.
40. Paton NIJ, Macallan DC, Jebb SA et al. Longitudinal changes in body composition measured with a variety of methods in patients with AIDS. Journal of AIDS and Hum Retrovir 1997; 14: 119-27.
41. Miller KD, Johnes E, Yanowski JA et al. Visceral abdominal-fat accumulation associated with use of Indinavir. Lancet 1998; 351: 871-5.
42. Navia MA, Fitzgerald PMD, Mc Keever BM et al. Three dimensional structure of aspartyl protease from human immunodeficiency virus (HIV-1). Nature 1989; 337: 615-20.
43. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance, Lancet 1998; 351: 1881-3.
44. Ledru E, Lecoeur H, Christeff N, Gougeon ML. Accumulation of TNFα-producing T cells as a consequence of defective regulation by apoptosis during HAART. Relation with the lipodystrophy syndrome. Workshop CNR-UNESCO: Microbial escape mechanism and new therapy of AIDS and tuberculosis. Ischia, 18-20 April 1999.
45. Liguori M, Urso R, Fatigante G. Insulino-resistenza, anomalie recettoriali e post-recettoriali. Minerva Endocrinologica 1998; 23: 37-52.
46. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-54.
47. Bell DR, Elcombe CR. Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators. Biochem J 1991; 280: 249-53.
48. Schoonjans K, Staels B, Auwerx J. Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Research 1996; 37: 907-25.
49. Matsugawa Y, Shimomura I, Nakamura T, Keno Y, Katami K, Toumaga K. Patophysiology and patogenesis of visceral gut obesity. Obesity Res 1995; 3 (suppl 2): 187-94.
50. Gagnon AM, Angel JB, Sorisky A. Protease inhibitors and adipocyte differentiation in cell culture. Lancet 1998; 352: 1032.
51. th Conference on Retroviruses and Opportunistic Infections. January 31-February 4, 1999, Chicago. Abstract 666.
52. Stocker DN, Meyer PJ, Stoller R, Fattinger KE. "Buffalo hump" in HIV-1 infection (correspondence). Lancet 1998; 352: 320-1.
53. th Conference on Retroviruses and Opportunistic Infections. January 31-february 4, 1999, Chicago. Abstract 672.
54. Miller KK, Daly PA, Sentochnik D, Doweiko J, Samore M, Basgoz NO, Grinspoon SK. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 68-72.
55. Gabay C, Kushner I. Mechanism of Disease: Acute-phase proteins and other systemic response to inflammation NEJM 1999; 340: 448-54.
56. Summary of the Second Report of the National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults. JAMA 1993; 269: 3015.
57. th Conference on Retroviruses and Opportunistic Infections. January 31-february 4, 1999, Chicago. Abstract 673.
58. th Conference on Retroviruses and Opportunistic Infections. January 31-February 4, 1999, Chicago. Abstract 675.